CEO since April 2021
Ulrika has a MSc Pharm (1991) and a PhD Pharm (1997) from the Faculty of Pharmacy, University of Uppsala. She has 15 years’ experience in drug discovery and development in the pharma industry. Her previous assignments include project leader, line manager and several senior roles in among others Biovitrum, Stockholm, Sweden and Prosidion Ltd, Oxford, UK. In 2012 Ulrika joined Professor Helleday at Karolinska Institutet to establish a drug discovery group in an academic setting and became the project leader for MTH1 project, the present lead clinical project at Oxcia. Ulrika was Deputy PI in the Helleday lab and became the Acting Principal Investigator/Group leader for the Helleday Lab, Department Oncology Pathology, Karolinska Institutet during Aug 2018- Aug 2020. Ulrika is a previous member of the steering group of Department Oncology Pathology, KI and previous member of KI cancer executive board. Ulrika is one of the co-founders of Oxcia AB and was chairmen of the board between 2013-March 2021. She is a board member of Thomas Helleday Foundation for Medical Research and steering group member of Chemical Biology Consortium Sweden (2022-2024). Ulrika currently holds the position as CEO at Oxcia AB.
Holdings : 0 A-shares, 450 000 B-shares and 175 000 warrants
Dependent in relation to the Company and its management and the Company’s major shareholders.